Ruxolitinib for a serious immune reaction after CAR T therapy
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a drug called ruxolitinib for a rare but serious condition called IEC-HS that can happen after CAR T cell treatment. The goal is to see if ruxolitinib can calm this overactive immune response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a condition called IEC-HS after CAR T therapy, confirmed by specific guidelines.
- You have high ferritin levels in your blood and at least two other symptoms like fever, organ problems, or low blood counts.
- You are able to take pills or have a feeding tube placed if needed.
- You have not received an experimental drug for IEC-HS before.
- You do not have a life expectancy longer than 6 months (the trial is for those with a shorter outlook).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the drug ruxolitinib, given before and after a stem cell transplant, can help prevent graft-versus-host disease (GVHD) in people with blood cancers. GVHD is a common complication where donor cells attack the patient's body.
This trial tests a combination of a targeted drug (ruxolitinib) with a less intense version of standard chemo for adults with Hemophagocytic Lymphohistiocytosis (HLH). It aims to control the overactive immune response while reducing side effects.
This Phase 2 study tests ruxolitinib as a first treatment for primary HLH, a rare, sometimes life-threatening immune overreaction. It may help calm the immune system and improve symptoms by blocking key immune signals.
This trial studies ruxolitinib to treat illnesses where the body makes too many eosinophils (a type of white blood cell) and symptoms or organ damage happen. It may help shrink disease activity when steroids are not enough, cannot be tolerated, or the illness comes back.
This Phase 2 study tests ruxolitinib (a targeted medicine) in people with essential thrombocythemia or polycythemia vera who still have troublesome symptoms. It aims to see whether it can reduce symptoms by changing disease activity and blood-related inflammation.
This Phase 1 study tests CK0804 (plus T-regs, a type of immune cell approach) for people with myelofibrosis whose disease is not adequately controlled on ruxolitinib. It may help improve blood counts, symptoms, and/or the size of an enlarged spleen.
Hear when a new Immune Effector Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.